Loading…
Develops therapies for rare bleeding disorders including Glanzmann thrombasthenia, a genetic platelet disease.
Develops therapies for rare bleeding disorders including Glanzmann thrombasthenia, a genetic platelet disease.
Has no product on sale, so it funds studies from money raised from investors; income would first come from licensing or partnership payments and later from drug sales if a product is approved. Its drugs target conditions with few patients, so one approved product would serve a small group at a high price per patient.
Moat: none (IP / patents). Addresses rare bleeding disorders with limited approved options, but is clinical-stage with small target populations.
Headquarters: Boston, Massachusetts, US · Founded: 2020 · Employees: 72
Size Hemab Therapeutics (COAG) is a United States Health Care company (Biotechnology) with a market value of $2.29B, the 1713th largest of 3,117 United States companies the cockpit tracks. Shares closed at $49.02 on 6 Nov 2026.
Performance Over six months the shares gained 95.1%, against +7.0% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Short interest Short interest is 6.8% of the free float (15 Oct 2026).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | n/a | -$304,000 | -$248,000 |
| EBITDA | n/a | -$69.8M | -$50.1M |
| Net income | n/a | -$63.9M | -$48.7M |
| Free cash flow | n/a | -$61.5M | -$45.9M |
| Capital expenditure | n/a | $16,000 | $282,000 |
| Total debt | $1.03M | $361M | $206M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Hemab Therapeutics COAG | $2.29B | +95% | n/a | n/a | n/a | n/a |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 4.0× | 0.1% |
| Sanofi SAN.PA | $113B | +14% | +15% | 27% | 2.6× | -5.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | COAG | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +58.7% | +1.3% | 2nd highest of 21 |
| 6-month return | +95.1% | +7.0% | 3rd highest of 21 |
| Distance from 52-week high | -11.6% | -28.5% | 7th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hemab Therapeutics COAG | United States | $2.29B | +95% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $2.28B | +105% | +13,520% | -57% | 19.5× | 18.7% | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +41% | +8% | 19% | 4.9× | 12.5% | +44.5% |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.32B | -32% | -49% | 51% | 0.3× | n/a | n/a |
| Sinocelltech 688520.SS | China | $2.25B | -23% | -40% | -75% | 15.6× | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.35B | -12% | -97% | -206,220% | 10,375.3× | n/a | n/a |
| SKBS 302440.KS | South Korea | $2.22B | -11% | +23% | -25% | 4.5× | n/a | n/a |
| Immunome IMNM | United States | $2.21B | -17% | -100% | n/a | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.21B | +8% | +21% | 45% | 5.5× | 5.1% | +41.4% |
| BGI Genomics 300676.SZ | China | $2.39B | -4% | 0% | -14% | 3.7× | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $2.19B | +6% | +56% | -725% | 25.1× | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.19B | +25% | +259% | 60% | n/a | n/a | n/a |
| Pharvaris PHVS | United States | $2.41B | +14% | n/a | n/a | n/a | n/a | n/a |
| Vera Therapeutics VERA | United States | $2.15B | -18% | n/a | n/a | n/a | n/a | n/a |
| MBX Biosciences MBX | United States | $2.47B | +25% | n/a | n/a | n/a | n/a | n/a |
| Hitgen 688222.SS | China | $2.12B | +23% | +42% | 27% | 19.1× | 38.7% | +16.8% |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $2.11B | -9% | -9% | 6% | 5.6× | 25.3% | +3.4% |
| Palvella Therapeutics PVLA | United States | $2.53B | +45% | -100% | n/a | n/a | n/a | n/a |
| Vir Biotechnology VIR | United States | $2.07B | +34% | +1,496% | -92% | 5.4× | n/a | n/a |
| Replimune REPL | United States | $2.05B | +547% | n/a | n/a | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $2.04B | -1% | n/a | n/a | n/a | n/a | n/a |